# EDGAR Filing Document

**Accession Number:** 0001743881
**File Stem:** 0001470831-26-000373
**Filing Date:** 2026-4
**Character Count:** 8505
**Document Hash:** fe69fff5cea99ff8e0a3427ede388bdf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001470831-26-000373.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001470831-26-000373

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001743881
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91059
- **FILM NUMBER:** 26868050

**BUSINESS ADDRESS:**
- **STREET 1:** 3160 PORTER DR.
- **STREET 2:** SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 391-9740

**MAIL ADDRESS:**
- **STREET 1:** 3160 PORTER DR.
- **STREET 2:** SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BridgeBio Pharma LLC
- **DATE OF NAME CHANGE:** 20180618
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kumar Neil
- **CENTRAL INDEX KEY:** 0001742485

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **STREET 1:** C/O BRIDGEBIO PHARMA, INC.
- **STREET 2:** 3160 PORTER DR, STE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Issuer:** BridgeBio Pharma, Inc.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 03/31/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>NEIL KUMAR | Names of Reporting Persons<br>NEIL KUMAR |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4208849.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>5074133.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4208849.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>5074133.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>9282982.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>9282982.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** (1) Consists of (i) 234,451 shares of Common Stock held directly by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of  March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held by the Kumar Haldea Revocable Trust, of which Dr. Kumar is a co-trustee and (v) 635,686 shares of Common Stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a co-trustee.
(2) Percentage ownership is based on (i) 195,707,702 shares of Common Stock outstanding as of March 31, 2026, (ii) 3,903,183 shares of Common Stock underlying stock options held by Dr. Kumar that are exercisable within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i) and (iii) 71,215 shares of Common Stock underlying restricted stock units held by Dr. Kumar that are subject to vesting and settlement within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

---

**Item 1(a). Name of Issuer:**
BridgeBio Pharma, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
3160 Porter Street, Suite 250, Palo Alto, California, 94304

**Item 2(a). Name of Person Filing:**
NEIL KUMAR

**Item 2(b). Address of Principal Business Office:**
3160 Porter Street, Suite 250, Palo Alto, California 94304

**Item 2(c). Citizenship:**
U.S.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

9,282,982 shares of Common Stock, which represents (i) 234,451 shares of Common Stock held of record by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held of record by Kumar Haldea Revocable Trust and (v) 635,686 shares of Common Stock held of record by the Kumar Haldea Family Irrevocable Trust.

**(b) Percent of class:**

4.6%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

4,208,849

**(ii) Shared power to vote or to direct the vote:**

5,074,133

**(iii) Sole power to dispose or to direct the disposition of:**

4,208,849

**(iv) Shared power to dispose or to direct the disposition of:**

5,074,133

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

—

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**NEIL KUMAR**

**Date:** 04/16/2026

**By:** /s/ Neil Kumar

**Name & Title:** Neil Kumar